Neurology · AntiepilepticRegulatory Approvalregulatorymid-term

FDA Accepts Supplement for Levetiracetam ANDA204754 by Aiping Pharm

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/21/2026, 12:32:34 AM

Assessment confidence: 68% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's acceptance of Aiping Pharm's supplemental application for a generic version of levetiracetam is significant as it introduces increased competition in the antiepileptic market. Pharma strategy teams must evaluate the potential impact on existing products and market dynamics. Regulatory context from FDA (FDA AP — LEVETIRACETAM (SUPPL)) supports the near-term read. Assessment grounded in 23 ranked evidence items (10 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of this new generic entry on market share and pricing strategies for existing levetiracetam products. The strongest clinical anchor is A Study to Investigate the Effect of AZD6234, AZD9550, and Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Part (ClinicalTrials.gov), sponsor/company relevance (astrazeneca). In Neurology · Antiepileptic, 8 regulatory and 2 competitive items passed relevance filtering for Levetiracetam.

Competitive Pressure

The most relevant competitive pressure comes from FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from FDA Approves OTC Naloxone Nasal Spray Rextovy for Opioid Overdose. This acceptance may enhance Aiping Pharm's position in the generic antiepileptic market, potentially increasing competition against established brands.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — LEVETIRACETAM (SUPPL) (FDA). Entity match (levetiracetam); Regulatory pathway relevance (nda). The acceptance of this application indicates a regulatory pathway for Aiping Pharm, which may lead to market entry and necessitate compliance adjustments for existing brands.

Key Risks

Elevated medium regulatory exposure for Levetiracetam could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

The entry of a new generic competitor could pressure pricing and market share for current levetiracetam products, affecting revenue streams.
Upside for Levetiracetam may improve if A Study to Investigate the Effect of AZD6234, AZD9550, and Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Part (ClinicalTrials.gov) delivers favorable follow-through.
Portfolio teams should assess the impact of this new generic entry on market share and pricing strategies for existing levetiracetam products.

What Would Change This Assessment

This becomes more urgent if Monitor the timeline for FDA review completion and potential market entry date for Aiping Pharm's levetiracetam product.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — LEVETIRACETAM (SUPPL)
FDAhigh relevance
Entity match (levetiracetam); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LEVETIRACETAM (SUPPL)
FDAhigh relevance
Entity match (levetiracetam); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LEVETIRACETAM IN SODIUM CHLORIDE (ORIG)
FDAhigh relevance
Entity match (levetiracetam); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LEVETIRACETAM (SUPPL)
FDAhigh relevance
Entity match (levetiracetam); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LEVETIRACETAM (SUPPL)
FDAhigh relevance
Entity match (levetiracetam); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LEVETIRACETAM IN SODIUM CHLORIDE (ORIG)
FDAhigh relevance
Entity match (levetiracetam); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — TOPIRAMATE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — CYCLOBENZAPRINE HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source

A Study to Investigate the Effect of AZD6234, AZD9550, and Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Part
ClinicalTrials.govhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Aut
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Effect of NUV001 Supplementation in Patients Suffering From Sickle Cell Disease (SCD)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
The Efficacy of Vitamin D Supplementation to Sustain Performance Outcomes
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Near-Infrared Spectroscopy, Acute Taurine Supplementation, and Isolated Muscular Endurance and Fatigue Resistance in Young Healthy Adults
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Multimorbidity and Polypharmacy in People With HIV vs.
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Comparative Pharmacokinetic, Pharmacodynamic, and Safety Study of 1 Dose of Aspirin for Injection and Oral Aspirin Tablets in Healthy Adult Subjects
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA Approves OTC Naloxone Nasal Spray Rextovy for Opioid Overdose
Humanexa Signalsmedium relevance
Moderate corpus alignment

Effects of carnosine supplementation on physical endurance: a placebo-controlled randomized clinical trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Lavandula angustifolia as a dual pharmacological system: from essential oil to polyphenol-rich biomass.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Selected immunoendocrine and performance adaptations to upper-body plyometric training and β-alanine supplementation in male swimmers.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
12‑weeks fisetin supplementation and interval resistance with aerobic training: changes in Maresin‑1 and inflammatory markers in men with obesity: a randomized controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Levetiracetam

Commercial impact

medium

The entry of a new generic competitor could pressure pricing and market share for current levetiracetam products, affecting revenue streams.

Regulatory impact

medium

The acceptance of this application indicates a regulatory pathway for Aiping Pharm, which may lead to market entry and necessitate compliance adjustments for existing brands.

What to watch

Monitor the timeline for FDA review completion and potential market entry date for Aiping Pharm's levetiracetam product.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.